Dr. Weidong Han
MD, PhD
Director, Department of Bio-therapeutics
corporate_fareChinese PLA General Hospital (301 Hospital), Beijing
Weidong Han
MD, PhD
Prof. Weidong Han is the Director of the Department of Bio-therapeutics at the Chinese PLA General Hospital (301 Hospital) in Beijing, and one of China's most influential figures in CAR-T and adoptive cell therapy. His clinical and research work focuses on engineered T-cell therapies for blood cancers and selected solid tumours.
Prof. Han has built one of China's earliest and most productive cell-therapy programmes, leading first-in-human and early-phase trials of chimeric antigen receptor (CAR) T cells. His team developed bispecific CD19/CD22 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia and CART19/20 approaches for diffuse large B-cell lymphoma. He has extended CAR-T into harder-to-treat areas, including GPC3-targeted CAR-T for hepatocellular carcinoma and allogeneic, gene-edited (TCR-knockout) CAR-T platforms. Prof. Han is the corresponding author of the widely cited national review on the clinical development of CAR-T cell therapy in China, and his published work has been cited more than 15,000 times. He continues to serve as principal investigator on multiple active cell-therapy clinical trials at the 301 Hospital.
CancerFax can coordinate medical-report review and consultation support for international patients interested in advanced cell therapy options, subject to hospital availability and case acceptance.
Why Consider Prof. Weidong Han?
Prof. Han is internationally recognised for pioneering CAR-T and adoptive cell therapy in China, with a clinical research record spanning blood cancers and solid tumours.
Areas of Specialization
Engineered cell therapy for blood cancers and selected solid tumours
CAR-T Cell Therapy
Chimeric antigen receptor T-cell therapy for relapsed or refractory blood cancers.
- arrow_rightCD19-targeted CAR-T for B-cell lymphoma and leukaemia
- arrow_rightBispecific CD19/CD22 CAR-T for relapsed or refractory B-cell ALL
- arrow_rightCART19/20 approaches for diffuse large B-cell lymphoma
- arrow_rightAllogeneic, gene-edited (TCR-knockout) CAR-T platforms
- arrow_rightCAR-T strategies for selected solid tumours
TCR-T & Adoptive Cell Therapy
Redirected T-cell and adoptive cell-transfer approaches for cancers beyond standard CAR-T targets.
- arrow_rightT-cell receptor engineered therapy for selected antigens
- arrow_rightAdoptive cell-transfer protocols for advanced disease
- arrow_rightGPC3-targeted CAR-T for GPC3-positive hepatocellular carcinoma
- arrow_rightInvestigational cell therapy for advanced solid tumours
Procedures Performed
Cell therapy and advanced oncology services
Engineered Cell Therapy
Medical OncologyPlanning and delivery of CAR-T, TCR-T and adoptive cell-therapy protocols for eligible patients.
Eligibility & Diagnostic Work-Up
DiagnosisAssessment and biomarker work-up to determine suitability for cell therapy.
Complex & Relapsed Disease Management
Complex DiseaseManagement of relapsed or refractory blood cancers being considered for cell therapy.
Second Opinion
Second OpinionIndependent review for patients considering CAR-T or cell therapy abroad.
Research & Publications
Clinical research and peer-reviewed contributions in cell therapy
A more detailed publication and clinical-trial list may be available on request via CancerFax.
Education & Training
Prof. Han is a clinician-scientist trained within China's medical and biomedical research system, holding both MD and PhD qualifications.
Clinical Experience
Prof. Han leads the cell-therapy programme at the Chinese PLA General Hospital, where he has built one of China's earliest and most active CAR-T research and treatment centres.
Languages & International
Prof. Han consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting with doctors in China.
CancerFax can coordinate professional medical interpreter support for international patients.
How CancerFax Helps You Access Dr. Weidong Han
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Weidong Han's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Weidong Han's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Weidong Han before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Weidong Han's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Weidong Han's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Weidong Han's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Weidong Han
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Han at the Chinese PLA General Hospital in Beijing, subject to hospital availability and case acceptance.
Prof. Han specialises in CAR-T and TCR-T cell therapy and adoptive cell therapy. His focus includes B-cell lymphoma and leukaemia, relapsed or refractory blood cancers, and selected solid tumours such as GPC3-positive hepatocellular carcinoma.
CAR-T cell therapy uses a patient's own immune cells, re-engineered to recognise and attack cancer cells. It is most established for certain relapsed or refractory blood cancers. Suitability depends on the diagnosis, prior treatment, and specific biomarkers, and requires expert review of complete medical records.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the hospital, subject to availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, treatment history, and relevant biomarker results. The final consultation format and availability depend on the doctor's institution.
Prof. Han is a principal investigator on several cell-therapy clinical trials at the Chinese PLA General Hospital. Trial eligibility is strict and decided by the trial team. CancerFax can help review whether a patient's case may be relevant for assessment, but trial access can never be guaranteed.
Connect with Weidong Han Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.